Physician profile
Hillary E Pane
NPI 1659539401
$1,241.68
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $42.42 · 2021: $496 · 2022: $149 · 2023: $382 · 2024: $54.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $307.42 | 2019-2021 | |
| Abbvie INC. | $254.58 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $124.85 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $100.43 | 2022 | |
| Corium, LLC | $49.43 | 2023 | Azstarys, Adlarity |
| Lilly USA, LLC | $48.76 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $37.06 | 2021-2023 | Austedo Xr |
| Boston Scientific Corporation | $35.43 | 2024 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.49 | 2023 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $25.37 | 2021 | |
| Neurocrine Biosciences, INC. | $23.09 | 2023 | Ingrezza |
| Exact Sciences Corporation | $19.48 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $13.93 | 2021 | |
| Novo Nordisk INC | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Pane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.